A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C

Clinical trial NCT01842451 · COMPLETED

Trial details

NCT number: NCT01842451
Sponsor: Vertex Pharmaceuticals Incorporated
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Hepatitis C CHC HCV Hepatitis C

Start date: 2013-06-01
Primary completion: 2014-05-01
Enrollment: 23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.